[1]张成杰,安庆华,郑玉明,等.苯磺酸左旋氨氯地平与缬沙坦对高血压患者脂质代谢和系统性应激的影响[J].医学信息,2020,33(21):140-142.[doi:10.3969/j.issn.1006-1959.2020.21.043]
　ZHANG Cheng-jie,AN Qing-hua,ZHENG Yu-ming,et al.Effects of Levamlodipine Besylateand Valsartan on Lipid Metabolism and Systemic Stress in Patients with Hypertension[J].Medical Information,2020,33(21):140-142.[doi:10.3969/j.issn.1006-1959.2020.21.043]
点击复制

苯磺酸左旋氨氯地平与缬沙坦对高血压患者脂质代谢和系统性应激的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年21期
页码:
140-142
栏目:
药物与临床
出版日期:
2020-11-01

文章信息/Info

Title:
Effects of Levamlodipine Besylateand Valsartan on Lipid Metabolism and Systemic Stress in Patients with Hypertension
文章编号:
1006-1959（2020）21-0140-03
作者:
张成杰; 安庆华; 郑玉明; 等
（山东省滨州市人民医院急诊科，山东 滨州 256610）
Author(s):
ZHANG Cheng-jie; AN Qing-hua; ZHENG Yu-ming; et al
(Emergency Department,Binzhou People’s Hospital,Binzhou 256610,Shandong,China)
关键词:
苯磺酸左旋氨氯地平; 缬沙坦; 高血压; 脂质代谢; 系统应激水平
Keywords:
Levamlodipine besylate; Valsartan; Hypertension; Lipid metabolism; Systemic stress level
分类号:
R544.1
DOI:
10.3969/j.issn.1006-1959.2020.21.043
文献标志码:
A
摘要:
目的 探讨苯磺酸左旋氨氯地平联合缬沙坦对原发性高血压患者脂质代谢和系统性应激的影响。方法 选择我院2017年9月~2018年12月收治的226例高血压患者作为研究对象，按照随机数字表法分为实验组和对照组，各113例。对照组采用苯磺酸左旋氨氯地平治疗，实验组在此基础上联合缬沙坦治疗，比较两组临床疗效、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）、总胆固醇（TC）、甘油三酯（TG）、舒张压（DBP）、收缩压（SBP）、C反应蛋白（CRP）、纤维蛋白原（FIB）、全血高切粘度（HBV）、红细胞聚集指数（EAI）、全血低切粘度（LBV）及不良反应发生情况。结果 实验组总有效率为93.81%，高于对照组的80.53%，差异有统计学意义（P＜0.05）；实验组HDL高于对照组，LDL、TC和TG水平低于对照组，差异有统计学意义（P＜0.05）；实验组SBP、DBP水平低于对照组，差异有统计学意义（P＜0.05）；实验组CRP、FIB、HBV、LBV和EAI水平均低于对照组，差异有统计学意义（P＜0.05）；实验组不良反应发生率为6.35%，低于对照组的20.63%，差异有统计学意义（P＜0.05）。结论 苯磺酸左旋氨氯地平联合缬沙坦治疗高血压效果显著，可有效改善患者脂质代谢与系统性应激水平，不良反应少，安全性高。
Abstract:
Objective To investigate the effect of levamlodipine besylate combined with valsartan on lipid metabolism and systemic stress in patients with essential hypertension.Methods A total of 226 hypertensive patients admitted to our hospital from September 2017 to December 2018 were selected as the research objects and were divided into experimental group and control group according to the random number table method, with 113 cases in each group. The control group was treated with levamlodipine besylate, and the experimental group was combined with valsartan on this basis. The clinical efficacy, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and total cholesterol (TC) were compared between the two groups, triglycerides (TG), diastolic blood pressure (DBP), systolic blood pressure (SBP), C-reactive protein (CRP), fibrinogen (FIB), whole blood high shear viscosity (HBV), erythrocyte aggregation index (EAI),whole blood low shear viscosity (LBV) and adverse reactions.Results The total effective rate of the experimental group was 93.81%, which was higher than 80.53% of the control group,the difference was statistically significant (P<0.05);The HDL of the experimental group was higher than that of the control group, and the levels of LDL, TC and TG were lower than the control group, the difference was statistically significant (P＜0.05); the levels of SBP and DBP of the experimental group were lower than the control group, the difference was statistically significant (P＜0.05); CRP, FIB, HBV, LBV and EAI levels of the experimental group were lower than those of the control group, the difference was statistically significant (P<0.05); the adverse reaction rate of the experimental group was 6.35%, which was lower than 20.63% of the control group,the difference was statistically significant (P<0.05).Conclusion The combination of levamlodipine besylate and valsartan had a significant effect in the treatment of hypertension, which could effectively improve the lipid metabolism and systemic stress level of patients with few adverse reactions and high safety.

参考文献/References:

[1]Zhong F,Zhuang L,Wang Y,et al. Homocysteine levels and risk of essential hypertension: A meta-analysis of published epidemiological studies[J].Clin Exp Hypertens,2017,39(3):160-167.[2]Higaki A,Caillon A,Paradis P,et al.Innateand Innate-Like ImmuneSystem in Hypertension and Vas- cular Injury[J].Curr Hypertens Rep,2019,21(6):4.[3]He LI,Wei WR,Can Z.Effects of 12-week brisk walking training on exercise blood pressure in elderly patients with essential hypertension:a pilot study[J].Clin Exp Hypertens,2018,40(5):673-679.[4]Xiao WY,Ning N,Tan MH,et al.Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose[J].Hypertens Res,2016,39(4):321-326.[5]Schmieder RE,Wagner F,Mayr M,et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study[J].Eur Heart J,2017,38(9):3308-3317.[6]Tong M.Progress in diagnosis and treatment of essential hypertension[J].Liaoning Med J,2018,8(2):169-170.[7]Lírio LM,Forechi L,Zanardo TC,et al.Chronic fructose intake accelerates nonalcoholic fatty liver disease in the presence of essential hypertension[J].J Diabetes Complications,2016,30(8):85-92.[8]Xu SM,Wang YL,Li D,et al.Randomized,two-way crossover bioequivalence study of levamlodipine besylate tablets in healthy Chinese subjects[J].Int J Clin Pharmacol Ther,2017,55(7):818-824.[9]Burnier M,Bakris G,Williams B.Redefining diuretics use in hypertension:why select a thiazidelike diuretic[J].J Hypertens,2019,2(1):1-13.[10]Shi R,Liu K,Shi D,et al.Effects of Amlodipine and Valsartan on Blood Pressure Variability and Pulse Wave Velocity in Hypertensive Patients[J].Am J Med Sci,2017,353(9):6-11.[11]Yu Q,Zhang J,Yue L,et al.Efficacy and Safety of Zhenyuan Capsule for Coronary Heart Disease with Abnormal Glucose and Lipid Metabolism: Study Protocol for a Randomized, Double-Blind, Parallel-Controlled, Multicenter Clinical Trial[J].Evid Based Complement Alternat Med,2018,18(3):171-176.[12]Adolf C,Asbach E,Dietz AS,et al.Worsening of lipid metabolism after successful treat ment of primary aldosteronism[J].Endocrine,2016,54(10):198-205.

相似文献/References:

[1]乔 君,高 翔,王 瑜,等.缬沙坦对原发性高血压患者外周PBMC中IL-17表达的影响[J].医学信息,2018,31(07):65.[doi:10.3969/j.issn.1006-1959.2018.07.021]
　QIAO Jun,GAO Xiang,WANG Yu,et al.The Effect of Valsartan on the Expression of IL-17 in Peripheral PBMC of Patients with Essential Hypertension[J].Medical Information,2018,31(21):65.[doi:10.3969/j.issn.1006-1959.2018.07.021]
[2]高占群,李 霜,刘 杨.立普妥与瑞舒伐他汀联合缬沙坦治疗糖尿病 并发心力衰竭的临床疗效[J].医学信息,2019,32(15):140.[doi:10.3969/j.issn.1006-1959.2019.15.045]
　GAO Zhan-qun,LI Shuang,LIU Yang.Clinical Efficacy of Lipitor and Rosuvastatin Combined with Valsartan in the Treatment of Diabetes Complicated with Heart Failure[J].Medical Information,2019,32(21):140.[doi:10.3969/j.issn.1006-1959.2019.15.045]
[3]范卢明,王 慧,薛 帆,等.缬沙坦联合二甲双胍治疗肥胖型高血压效果的Meta分析[J].医学信息,2022,35(15):68.[doi:10.3969/j.issn.1006-1959.2022.15.014]
　FAN Lu-ming,WANG Hui,XUE Fan,et al.Meta-analysis of the Effect of Valsartan Combined with Metformin in the Treatment of Obese Hypertension[J].Medical Information,2022,35(21):68.[doi:10.3969/j.issn.1006-1959.2022.15.014]
[4]田云朋,卢成志,赵向东.缬沙坦治疗慢性心功能不全合并阵发性房颤的临床疗效[J].医学信息,2019,32(13):135.[doi:10.3969/j.issn.1006-1959.2019.13.041]
　TIAN Yun-peng,LU Cheng-zhi,ZHAO Xiang-dong.Clinical Efficacy of Valsartan in the Treatment of Chronic Heart Failure Complicated with Paroxysmal Atrial Fibrillation[J].Medical Information,2019,32(21):135.[doi:10.3969/j.issn.1006-1959.2019.13.041]
[5]王 力,袁志强,黄晓鹏,等.前列地尔联合缬沙坦对慢性肾小球肾炎患者肾功能指标的影响[J].医学信息,2019,32(21):147.[doi:10.3969/j.issn.1006-1959.2019.21.048]
　WANG Li,YUAN Zhi-qiang,HUANG Xiao-peng,et al.Effect of Alprostadil Combined with Valsartan on Renal Function Indexes in Patients with Chronic Glomerulonephritis[J].Medical Information,2019,32(21):147.[doi:10.3969/j.issn.1006-1959.2019.21.048]
[6]孔令玲.参芪地黄汤联合缬沙坦治疗气阴两虚型早期糖尿病肾病的疗效[J].医学信息,2020,33(02):160.[doi:10.3969/j.issn.1006-1959.2020.02.050]
　KONG Ling-ling.Efficacy of Shenqi Dihuang Decoction Combined with Valsartan in the Treatment of Early Diabetic Nephropathy with Deficiency of Qi and Yin[J].Medical Information,2020,33(21):160.[doi:10.3969/j.issn.1006-1959.2020.02.050]
[7]陈钰泱,石爱杰.缬沙坦联合前列地尔治疗慢性肾小球肾炎的效果[J].医学信息,2020,33(15):151.[doi:10.3969/j.issn.1006-1959.2020.15.048]
　CHEN Yu-yang,SHI Ai-jie.The Effect of Valsartan Combined with Alprostadil on Chronic Glomerulonephritis[J].Medical Information,2020,33(21):151.[doi:10.3969/j.issn.1006-1959.2020.15.048]

更新日期/Last Update: 1900-01-01